Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From ImCyse S.A.

Avacta Pursues Combination Therapy Approach Targeting Solid Tumors

Avacta CEO Alastair Smith talks to In Vivo about the company’s precision chemistry, immunotherapy and diagnostic programs.

Cancer Diagnostics

Finance Watch: $2.2bn In New Funding Sources In February, So Far

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Financing Innovation

Avacta/Daewoong’s Joint-Venture AffyXell Paves Way For Next-Generation Stem Cell Therapy

A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.

Companies Deals

Pfizer Buys Into Promise Of Imcyse Imotopes

The US giant is taking a stake in Imcyse and taking over a program to develop RA drugs in a deal that validates the Belgian group's imotope technology.

Deals Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register